Nuwellis Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Nuwellis Inc trades at $1.42 (market cap $542.80K), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.87. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | SPXL | |
|---|---|---|
Market Cap | $542.80K | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $220.50 | $296.39 |
52-Week Low | $1.42 | $170.20 |
Enterprise Value | -$1.27M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.41, down 0.7% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with preliminary Q2 2026 revenue up 14% year-over-year, but remains unprofitable with a net income margin of -217.22%. Recent developments include a reverse stock split, new CEO appointment, and expansion of its Aquadex platform into new pediatric markets. Cash flow from operations is negative, though recent financing activities have provided capital.
The outlook is mixed: growth initiatives and analyst support offer potential, but persistent losses and high cash burn pose significant risks. Investors should weigh the company's expansion against its financial sustainability.
SPXL, a leveraged ETF tracking the S&P 500, trades at $295.99, down 0.07% on the day, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF reflects the S&P 500's record highs, driven by strong corporate earnings and AI optimism, though valuation concerns persist. Recent news highlights mixed sentiment, with JPMorgan raising its S&P 500 target to 8,000 while some warn of overvaluation risks.
The outlook for SPXL hinges on S&P 500 performance, offering amplified gains in a bullish market but heightened losses in downturns. Key opportunities include continued AI-driven earnings growth, while risks involve market volatility, inflation reports, and potential pullbacks from elevated levels. Investors should weigh leverage effects against broader index trends.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →